R1 pancreatic cancer patients benefit from chemoradiation when initiation of adjuvant therapy is delayed.

[1]  W. Jarnagin,et al.  Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  S. Karam,et al.  Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis. , 2022, The British journal of surgery.

[3]  L. Ocuin,et al.  The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis , 2021, Cancer reports.

[4]  M. Falconi,et al.  Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology. , 2021, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[5]  K. Lillemoe,et al.  Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation , 2021, Annals of Surgical Oncology.

[6]  D. Geller,et al.  Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study , 2020, Journal of Gastrointestinal Surgery.

[7]  A. Zwinderman,et al.  Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Anurag K. Singh,et al.  Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer , 2019, JAMA network open.

[9]  D. Bentrem,et al.  Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? , 2018, Surgery.

[10]  H. Friess,et al.  R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer , 2017, Annals of surgery.

[11]  T. Conroy,et al.  Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Lowy,et al.  Borderline resectable pancreatic cancer: definitions and management. , 2014, World journal of gastroenterology.

[13]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[14]  I Ihse,et al.  Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial , 2001, Annals of surgery.

[15]  T. Takada,et al.  Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. , 2008, Archives of surgery.

[16]  Wolfgang Schima,et al.  Pancreatic adenocarcinoma , 2006, European Radiology.